Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | F7 | P08709 | 5/20 | 1.00 |
| ▸ | F3 | P13726 | 5/20 | 1.00 |
| ▸ | FABP4 | P15090 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685715 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL15880317 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL20856202 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498259 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498256 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Arachidic Acid SCHEMBL20528087 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL25294178 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498258 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Dihomo-Gamma-Linolenic Acid SCHEMBL20656585 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL6112730 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222016-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2025-07-10 | — | — | US | disclosed |
| US-12268700-B2 | 3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-08 | — | — | US | disclosed |
| EP-3774830-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023110-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2019190986-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222016-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | UGCG, FUT5, FUT6 | PPARG 1401/4885PPARD 1886/4885PPARA 643/4885 |
| US-20210023110-A1 | 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF | UGCG, FUT6, FUT5 | PPARG 1438/4885PPARD 1524/4885PPARA 717/4885 |
| US-12268700-B2 | 3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof | UGCG, FUT6, FUT5 | PPARG 1438/4885PPARD 1524/4885PPARA 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.